AQP4 and neuromyelitis optica: Consistent with our in vitro and ex vivo results, WP1066 treatment robustly inhibited STAT3 phosphorylation and reduced CHI3L1 induction in systemic NMO mice treated with AQP4-IgG, compared with those receiving Ctrl-IgG (Figure 6E).